Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
153Sm-EDTMP and Radiotherapy for High Risk Osteosarcoma
NCT01886105Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of samarium-153 lexidronam in osteosarcoma (OS), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Percentage of Treated Participants With 6-month Progression Free Survival. Started Aug 2013; status: terminated.
02
Drugs
samarium-153 lexidronam
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT01886105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01886105.